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InterventionalManagement of Postbiopsy Arteriovenous
Fistulas in Transplanted Kidneys
and Effectiveness of Endovascular Treatment:
A Single-center ExperienceRita Fossaceca,1 Giuseppe Guzzardi,1 Paolo Cerini,1 Giuseppe Parziale,1 Emanuele Malatesta,1
Ivan Di Gesu,1 Marco Quaglia,2 and Alessandro Carriero,1 Novara, ItalyBackground: We sought to evaluate the best therapeutic management of postbiopsy arteriove-
nous fistulas (AVFs) in transplanted kidneys.
Methods: Between January 2005 and December 2011, we observed 17 cases of postbiopsy
AVF in transplanted kidneys (9 asymptomatic; 8 symptomatic). Asymptomatic cases were
managed conservatively, while patients with symptomatic AVF underwent endovascular treat-
ment. We used a technique that consisted in a superselective transcatheter embolization of
the afferent branch. We evaluated the technical success (postoperative closure of AVF), the
immediate clinical efficacy (cessation of symptoms), and clinical efficacy at follow-up (measure-
ment of serum creatinine at 7 days and 6 and 12 months compared with preoperative levels
using t-tests).
Results: Asymptomatic AVFs resolved spontaneously, while the endovascular treatment in
symptomatic AVFs showed a complete technical and clinical success with prompt remission of
the presented symptoms. We observed a statistically significant reduction in serum creatinine at
7 days and 6 and 12 months postoperatively (mean creatininedpreoperative: 3.23 ± 1.4 mg/dL;
7 days: 2.25 ± 0.8 mg/dL; 6 months: 1.65 ± 0.28 mg/dL; 12 months: 1.4 ± 0.26 mg/dL; in all cases
P < 0.05).
Conclusions: In our experience, asymptomatic AVFs could be managed conservatively with
close follow-up while the endovascular treatment for symptomatic AVFs is both safe and effec-
tive in the short- and long-term.Kidney transplantation is the treatment of choice for
end-stage renal failure; however, it is burdened by
a wide variety of complications, both vascular and
nonvascular, that may compromise long-term func-
tion.1 Vascular complications are represented by
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2 Fossaceca et al. Annals of Vascular Surgerymain cause of iatrogenic vascular complications
(AVF and pseudoaneurysms), with an incidence of
1e15%.1 In most cases, AVFs are asymptomatic
and undergo spontaneous resolution2; in some
cases, however, they may present with massive
hematuria, refractory hypertension, and decreased
renal function, and may require treatment.3 Endo-
vascular treatment is a viable alternative to surgery
because, with modern techniques of coaxial super-
selective catheterization of the afferent vessels, it is
possible to completely embolize the AVF with
minimal renal ischemic injury.4
There are few published studies regarding the
endovascular treatment of postbiopsy AVFs,4e12
most of which are represented by case reports or
short follow-up studies; the largest published study
to date by Lorenzen et al.12 was comprised of 20
patients with 24 AVFs.
The aimof thisworkwas to evaluate the best ther-
apeutic management of AVFs and to test the clinical
efficacy of endovascular treatment by carrying out
a literature review.
METHODS
Between January 2005 and December 2011 at
our hospital, 17 patients developed a postbiopsy
AVF: 9 patients were asymptomatic and were
managed conservatively; 8 patients were symptom-
atic (6 men and 2 women; mean age: 47.5 years
[range: 32e65 years]), with a total of 8 AVFs and
underwent endovascular treatment.
Indications for renal transplant in this group of
17 patients were as follows: glomerular disease
(9 patients), diabetes type I (5 patients), polycystic
kidney disease (1 patient), refractory hypertensive
nephropathy (1 patient), and hemolytic-uremic
syndrome (1 patient). All patients were undergoing
triple immunosuppressive therapy and had no
major contraindication for transplant (i.e., they
were of the appropriate age, were HIV/hepatitis C
and hepatitis B virusenegative, and had good
cardiac and respiratory function).
Biopsy was performed at a mean interval from
transplantation of 238 ± 65 days (range: 4 dayse
52 months); biopsy specimens were obtained in all
cases under local anesthesia (10 mL of lidocaine
2%) under ultrasound guidance using a 14e18
gauge needle (CR Bard, Covington, UK); both the
upper pole than the lower pole of the transplanted
kidney were biopsied.
We cannot establish a certain relationship
between the size of the needles used and the devel-
opment of a fistula, because in our cases there was
an almost equal distribution between biopsiesobtained with 18-gauge needles (10 patients) and
14-gauge needles (7 patients).
In all 8 cases, the outcome of the biopsy did not
reflect a change in the medication of the patient.
All patients treated underwent a color Doppler
ultrasound diagnosis of AVF associated with wors-
ening renal function; in 3 cases, hematuria was
observed, and in the other 2 refractory hyperten-
sion. Patients with a color Doppler ultrasound diag-
nosis of AVF not associated with worsening of renal
function or clinical manifestations were managed
conservatively with close follow-up.
All fistulas that required treatment were of signif-
icant size and therefore symptomatic; asymptomatic
fistulas were usually smaller.
In all cases, the transplanted kidney was from
a cadaver donor; in 5 cases, it was housed in the
left iliac pouch and in 3 cases in the right iliac pouch.
The mean interval between biopsy and endovascu-
lar intervention was 92 days (range: 4e156 days).
All patients signed valid informed consent before
the procedure. For the retrospective nature of the
study, the opinion of the ethics committee of our
institution was not sought.
Procedures were all performed in the angiography
suite (Angiograph Integris V5000; Philips Medical,
Endhoven, the Netherlands) under local anesthesia
(10 mL of lidocaine 2%), in 5 cases by means of
retrograde ipsilateral common femoral artery punc-
ture (5-French introducer; Terumo Corp., Tokyo,
Japan) and in 3 cases using a contralateral approach.
Using selective catheterization of the external iliac
artery (catheter diagnostic 5-French Cordis; Johnson
and Johnson, Roden, the Netherlands), a diagnostic
angiography was performed. In coaxial technique,
a superselective catheter was inserted into the
afferent arterial branch of the fistula through
a 0.02500 Progreat microcatheter (Terumo Corp.) on
a 0.02100 microguidewire and then we proceeded to
the embolization of the AVF using fibered platinum
microcoils (Boston Scientific, Natick, MA).
The mean dose of contrast medium used (Visipa-
que 320 mgI/mL; GE Healthcare, Carrigtohill,
Ireland) was 110 mL (range: 80e130 mL). In all
cases, postprocedural control angiography was per-
formed and hemostasis was obtained by manual
compression.
The evaluated parameters included technical
success, defined as complete cessation of flow in
correspondence of the fistula; postprocedural com-
plications, clinical efficacy, and immediate cessation
of symptoms as assessed; and long-term clinical effi-
cacy, which was assessed by measurement of serum
creatinine at 7 days, 6 and 12 months, and then
annually after the procedure.
Fig. 1. Endovascular treatment of postbiopsy arteriove-
nous fistula (AVF). Using contralateral femoral access,
selective catheterization of the transplanted renal artery
is performed. (A) Angiography confirmed the presence
of an AVF in the lower pole of the kidney. (B) Using
selective catheterization, we proceeded to microembolize
the AVF using a spiral VortX occlusion coil (Boston
Scientific, Natick, MA; 4-  3.7-mm; patient 1). (C) Final
control angiography documented complete exclusion
from the circulation of the AVF, with preserved renal
perfusion (D).
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operation were compared using a t-test and theWil-
coxon rank-sum test; P< 0.05was considered statis-
tically significant.RESULTS
Technical success was achieved in all cases: at the
end of the treatment, AVFs were completely
excluded from the circulation (Fig. 1). There was
no need for additional embolization procedures.
Postprocedural renal ischemia, assessed as loss of
the parenchymal phase at the final angiography,
was partial and not associated with impaired renal
function postoperatively.
There were no postoperative complications.
Asymptomatic AVFs as of latest follow-up pre-
sented in stable condition, with normal renal func-
tion and spontaneous regression of the vascular
lesions. Table I shows the clinical outcomes of the
patients.Embolization was associated in all cases with
a rapid clinical success; in patients with massive
hematuria, there was a rapid cessation of bleeding,
while in those suffering from hypertension, there
was a progressive normalization of blood pressure
postoperatively.
All patients were subjected to recording of serum
creatinine levels at 7 days, 6 and 12 months
after treatment, and then annually thereafer.
The mean preoperative creatinine level was
3.23 ± 1.4 mg/dL (range: 1.8e5.6 mg/dl). Seven
days after surgery, the average creatinine level
was 2.25 ± 0.8 mg/dL (range: 1.4e4.2 mg/dL); the
comparison of preoperative creatinine values with
those after 7 days showed a statistically significant
reduction (P < 0.005; W value: 36). At 6 months,
the average creatinine level was 1.65 ± 0.28 mg/
dL (range: 1.2e2.0 mg/dL); at 12 months, this
was 1.4 ± 0.26 mg/dL (range: 1.0e1.8 mg/dL). At
both 6 and 12 months, the reduction of creatinine
was statistically significant compared to baseline
(P < 0.005; W value: 36).
Table I. Clinical outcome of treated patientsa
Patient no. Sex Age (yr)
Technical
success
Serum creatinine level (mg/dL)
Baseline 7-day 6 months 12 months
1 M 43.5 Yes 1.8 1.4 1.2 1.2
2 M 38.1 Yes 4.4 2.3 1.5 1.4
3 F 32.0 Yes 3.4 2.4 1.7 1.8
4 M 54.8 Yes 2.0 1.6 1.4 1.4
5 M 48.8 Yes 5.6 4.2 2.0 1.6
6 M 51.4 Yes 2.2 1.8 1.6 1.2
7 F 60.2 Yes 4.2 2.4 2.0 1.0
8 M 34.5 Yes 2.3 1.9 1.8 1.6
Mean 45.4 d 3.2 2.2 1.6 1.4
SD d d 1.38 0.87 0.28 0.26
P value d d d 0.005 0.007 0.006
F, Female; M, male; SD, standard deviation.
at-test comparing baseline serum creatinine values to those recorded at 7 days and 6 and 12 months showed statistically significant
differences in all cases.
4 Fossaceca et al. Annals of Vascular SurgeryAt a mean follow-up of 40 months (range: 12e
64 months), we observed complete long-term clin-
ical success at with normalization of renal function
(mean creatinine: 1.5 ± 0.6 mg/dL; P < 0.05), and
no patient required hemodialysis treatment.DISCUSSION
Biopsy is an essential procedure for the evaluation
of an eventual dysfunction of the transplanted
kidney, allowing for the precise identification of
the pathologic process in progress and adequate
therapeutic classification.1 AVFs and pseudoaneur-
ysms represent the most frequent vascular compli-
cations associated with biopsy, with an incidence
ranging of 1e15%.1 In most cases, AVFs resolve
spontaneously and do not require treatment but
only a conservative management with close color
Doppler ultrasound follow-up2; in a smaller
percentage of cases, however, an AVF can manifest
clinically with hypertension, hematuria, and reduc-
tion of renal function, and in such cases, treatment
is mandatory.3
The management of asymptomatic AVFs is
a matter of debate: Loffroy et al.7 recommend the
treatment of AVFs even if they are asympto-
matic, because they may cause renal ischemia,
heart failure, or undergo gradual growth with
massive bleeding and possible renal failure; other
authors,12,13 however, recommend treatment of
AVFs only if they are symptomatic or associated
with worsening of renal function. We agree with
the latter therapeutic management, because there
are no strong data in the literature in favor of
a preventive treatment in asymptomatic AVF, whilethere is a strong finding that about 70% of the AVFs
in native and transplanted kidneys undergo sponta-
neous resolution.1,5 This therapeutic approach we
have adopted has proven effective; the 9 asymptom-
atic AVFs managed conservatively, with close
follow-up, regressed spontaneously while the 8
symptomatic and treated AVFs showed a benefit
from the operation.
Currently, endovascular treatment is considered
the first therapeutic choice for postbiopsy AVFs
because it allows for complete exclusion from the
circulation, with minimum risk of renal ischemic
injury.13
The effectiveness of the treatment depends on the
embolization technique and the material used. In
our experience, we have implemented all treat-
ments in coaxial superselective transcatheter embo-
lisation technique10e12: this method allows to
obtain the selective exclusion from the circle of the
vascular lesion, saving the remaining renal paren-
chyma and thereby minimizing the risks and
complications associated with it.
In all cases we used as the embolic agent fibered
platinum microcoils, in line with the literature
data.4e12 Other techniques described in the litera-
ture include the following: in cases of high-output
AVFs, the use of an arterial occlusion balloon and
subsequent release of coils14 or an occlusion balloon
positioned on the arterial and venous side15; in cases
of high-flow AVFs, the use of an Amplatzer vascular
occluder (AGA Medical Corp., Plymouth, MN) with
dual access from the arterial and venous side16 or
the use of interlocking detachable coils.12,17 The
literature also describes the ability to embolize
AVFs by injection of cyanoacrylate12 or ethylene
vinyl alcohol copolymer.18
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of microcoils according to our greater experience
with these agents and the good results obtained in
all cases. In fact, we have had 100% technical
success with adequate exclusion from the circle of
the vascular lesions, in the absence of complications
and minimal postoperative renal ischemic injury.
Few studies have made a correlation between
endovascular treatment and improvement of renal
function. The results we observed in terms of
improvement of kidney function are in line with
those recently published by Lorenzen et al.12 that,
with the higher statistics as of now, observed
a good result in 19 of 20 patients with a mean
follow-up of 31 months. Other studies have docu-
mented less important results in terms of improve-
ment in renal function: Maleux et al.6 observed an
improvement in 9 of 13 patients, deSouza et al.8 in
4 of 7 patients, and Loffroy et al.7 in 4 of 12 patients.
Lorenzen et al.12 suggested as a possible factor
affecting the renal function the amount of contrast
medium administered, which in its series was
80 mL while in that of Loffroy et al.7 was 111 mL.
This hypothesis is not reflected in our study, where
the average dose of contrast medium administered
was 110 mL.
The major limitation of this study is the low
number of patients enrolled, which does not allow
us to make a final judgment on the correct thera-
peutic management; postbiopsy AVFs are, however,
infrequent complications and are therefore difficult
to capture in a larger, single-center series of patients.
In conclusion, our study shows that asymptom-
atic AVFs should be managed conservatively with
close color Doppler ultrasound every 3months until
regression of the fistula occurs; in symptomatic
AVFs, endovascular treatment is a safe and effective
option that is able to ensure the restoration of renal
function in both the short- and long-term. Angio-
graphic treatment has low risks and is able to mini-
mize ischemic damage to the kidney.REFERENCES
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